Bero Lisa A, Grundy Quinn
Charles Perkins Centre, Faculty of Pharmacy, University of Sydney, Sydney, Australia.
PLoS Biol. 2016 Dec 21;14(12):e2001221. doi: 10.1371/journal.pbio.2001221. eCollection 2016 Dec.
A current debate about conflicts of interest related to biomedical research is to question whether the focus on financial conflicts of interest overshadows "nonfinancial" interests that could put scientific judgment at equal or greater risk of bias. There is substantial evidence that financial conflicts of interest such as commercial sponsorship of research and investigators lead to systematic biases in scientific research at all stages of the research process. Conflation of "conflicts of interest" with "interests" in general serves to muddy the waters about how to manage conflicts of interest. We call for heightened disclosure of conflicts of interest and policy action beyond disclosure as the sole management strategy. We propose a different strategy to manage interests more broadly to ensure fair representation and accountability.
当前关于生物医学研究中利益冲突的一场争论是,关注经济利益冲突是否掩盖了那些可能使科学判断面临同等或更大偏见风险的“非经济”利益。有大量证据表明,诸如研究的商业赞助和研究者的经济利益冲突等经济利益冲突会在研究过程的各个阶段导致科学研究中出现系统性偏见。一般而言,将“利益冲突”与“利益”混为一谈会使关于如何管理利益冲突的问题变得模糊不清。我们呼吁加强对利益冲突的披露,并采取除披露之外的政策行动作为唯一的管理策略。我们提出一种更广泛地管理利益的不同策略,以确保公平代表性和问责制。